Boston Scientific Parkinson's DBS treatment wins CE mark

Boston Scientific ($BSX) gained a CE mark for its Vercise deep brain stimulation system as a Parkinson's disease treatment. It uses electrical signals on specific areas of the brain to address Parkinson's symptoms. The Natick, MA-based device company bills its system as the first on the commercial market able to use multiple independent current control. Vercise could reach an enormous amount of Parkinson's patients; as many as 6.3 million people globally, according to data Boston Scientific cites from the European Parkinson's Disease Association. Release

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.